EGFR and non-small cell lung carcinoma: In parallel, furmonertinib (AST2818), a brain-penetrant third-generation EGFR inhibitor, has demonstrated promising activity in EGFR-mutated NSCLC, including signals of efficacy in ex20ins disease and in intensified dosing strategies (7, 10–13).